News

TB R&D Weekly Update: Podcast interview on TB Drug Tolerance and Efflux Pumps

Photos of Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma

Listen to Lalita Ramakrishnan Podcast


Summary: The WGND had the opportunity to interview three researchers (Lalita Ramakrishnan, Paul Edelstein, and Christine Cosma) involved in the groundbreaking research on the role of efflux pumps in contributing to drug tolerance during TB treatment which was published in the April 1 issue of Cell. The article is entitled “Drug Tolerance in Replicating Mycobacteria Mediated by a Macrophage-Induced Efflux Mechanism.” Dr. Ramakrishnan is Professor in the Department of Microbiology, at the University of Washington. Dr. Edelstein is Director of the Clinical Microbiology Laboratory at the University of Pennsylvania. Dr. Cosma is a Research Scientist at the University of Washington. In the interview, we discuss the background of each guest interviewee, key results presented in the article, and next steps for clinical testing of compounds that inhibit efflux pumps and experiments for learning more about this mechanism for inducing drug tolerance.

Additional TB R&D News:

Critical Path Institute Announces Expansion of Regulatory Science Consortium for Tuberculosis

Sequella Licenses Rights to Commercialize SQ109 for Tuberculosis in Russia to Maxwell Biotech Venture Fund Subsidiary

The arsenal to fight microbes is very weak right now

TB diagnostics: all studies recruiting patients now

Registering New Drugs for Low-Income Countries: The African Challenge

More News
22 Jul 2024
The National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID) has issued a $30.8 million grant to the Preclinical Design and Clinical Translation of TB Regimens (PreDiCTR) consortium , a new consortium co-led by investigators from Weill Cornell Medicine; the...
27 Jun 2024
On May 17, the World Health Organization (WHO) released its updated  Bacterial Priority Pathogens List (BPPL) 2024 and for the first time in its history it included a drug resistant strain of Mycobacterium tuberculosis. Along with three other new families of antibiotic-resistant bacterial pathogens...
19 Mar 2024
For World TB Day 2024, the WGND is spotlighting a monumental achievement in TB drug research and development: the Global TB Drug Pipeline has never been bigger than it is today. The number of drug candidates being clinically evaluated for use in the treatment of adult pulmonary TB has surpassed...